• Firefly Luciferase mRNA as a Translational Control

  2026-09-30

  A mechanistic and strategic guide to using Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) as a high-confidence control for delivery, expression, cell-state, and translational development studies.

• Niclosamide for ATRX-Aware Cancer Assays

  2026-09-30

  Niclosamide is examined here through an ATRX-aware assay framework that connects STAT3 pharmacology with genotype-dependent drug sensitivity in glioma research. The article separates established product evidence from testable hypotheses, helping researchers design stronger target-engagement, apoptosis, and cell-cycle experiments.

• L-Phenylephrine: Sex-Aware α1A Assay Design

  2026-09-29

  L-Phenylephrine enables controlled investigation of adrenergic α1A receptor signaling across vascular, cardiac, and neural models. This article translates sex-dependent hypertension findings into a rigorous framework for selecting endpoints, controls, and assay conditions without conflating a pressor probe with direct mechanistic proof.

• Tankyrase Inhibition and Hippo Signaling in HCC

  2026-09-29

  Jia et al. showed that the tankyrase inhibitors XAV-939 and G007-LK suppress hepatocellular carcinoma cell growth while reducing YAP activity and increasing the Hippo-pathway regulators AMOTL1 and AMOTL2. The study’s main contribution is a mechanistic link between tankyrase inhibition and Hippo cascade modulation, extending interpretation beyond the canonical Wnt/β-catenin pathway.

• (S)-(+)-Ibuprofen: COX Inhibitor Workflows

  2026-09-28

  Build more reproducible inflammation, pain, and environmental toxicology assays with the pharmacologically active (S)-(+)-Ibuprofen enantiomer. This guide connects stereopure COX inhibition to practical dosing, controls, endpoint selection, and troubleshooting across research workflows.

• Abiraterone Acetate in Patient-Derived Prostate Models

  2026-09-28

  Abiraterone acetate is a CYP17 inhibitor for studying steroid supply and androgen signaling in prostate cancer research. This article examines how patient-derived spheroids can reveal model-specific drug responses—and why a negative result should prompt assay analysis rather than a sweeping conclusion.

• Protease Inhibitor Cocktail for Protein Assays

  2026-09-27

  Protect labile proteins during extraction while keeping divalent cations available for phosphorylation-sensitive and enzyme assays. This practical guide shows how to apply an EDTA-free, 100X DMSO cocktail to workflows inspired by recent atopic dermatitis hydrogel research—without implying the study tested this reagent.

• Purifying and Analyzing Mycobacterium tuberculosis WecA

  2026-09-26

  Zhao and colleagues report a regulated expression and affinity-purification workflow for Mycobacterium tuberculosis WecA, a difficult membrane enzyme involved in cell-wall biosynthesis. They establish an activity readout based on UMP detection and identify tunicamycin as a competitive inhibitor, providing a biochemical platform for further enzyme and inhibitor studies.

• GLP-1 (9-36) amide in cAMP assay design

  2026-09-25

  Use GLP-1 (9-36) amide to test how GLP-1 receptor blockade changes cAMP responses, while separating receptor-specific effects from ligand cross-reactivity. This practical guide pairs careful peptide handling with a controlled FRET workflow and clearly distinguishes product testing from the antagonist used in the cited reference study.

• GI Device Delivery of mRNA-LNPs in Mice and Pigs

  2026-09-25

  This study evaluates an ingestible microjet device for injecting mRNA-loaded lipid nanoparticles into the stomach and intestinal walls, then examines expression and biodistribution in mice and minipigs. The findings show that gastrointestinal delivery can produce route-dependent distribution, including mRNA in plasma and lymph nodes, and establish a preclinical basis for investigating oral device-mediated delivery as an alternative to conventional injections.

• JHU-083: Practical Guide to Reliable Cell Assays

  2026-09-24

  A scenario-driven guide to using JHU-083 (SKU BA7770) in glutaminase pathway research, with practical guidance for assay design, interpretation, and compound handling. It distinguishes product specifications from workflow recommendations and clarifies the limits of translating hepatotoxicity findings to neurological models.

• H-89 in Cell Assays: PKA Signaling with Context

  2026-09-24

  A practical guide to using H-89 (SKU BA3584) to investigate PKA-dependent signaling while distinguishing pathway effects from changes in cell viability or metabolism. It covers assay design, handling, interpretation, and product-selection considerations grounded in product data and a recent Wnt–O-GlcNAc study.

• ICG001: A Selective Wnt/β-Catenin Pathway Inhibitor

  2026-09-23

  ICG001 is a Wnt/β-catenin pathway inhibitor used to probe transcription driven by the β-catenin–CBP interaction. Its reported activity and research applications make it useful for pathway studies, but findings must be interpreted by model, assay conditions, and the distinction between preclinical evidence and clinical efficacy.

• CHIR-99021 (CT99021) in Stem Cell Signaling

  2026-09-23

  CHIR-99021, also called CT99021, is a selective GSK-3α/β inhibitor used to modulate Wnt/β-catenin signaling and stem-cell fate. Evidence supports concentration-sensitive use in pluripotency, lineage differentiation, and vascularized pancreatic progenitor workflows, but reported conditions are system-specific.

• Redox State Strategy for Hypoxic Tumors

  2026-09-22

  Hypoxia and immunometabolic competition can reshape tumor redox biology, but translational claims require direct measurement of glutathione pools. This thought-leadership guide connects tumor microenvironment mechanisms with experimental strategy, showing how the GSH and GSSG Assay Kit supports quantitative reduced glutathione detection, oxidized glutathione measurement, and reproducible redox state analysis.

7927 records 1/529 page Next 12345 下5页 Last page